Rockefeller Capital Management L.P. Sells 6,067 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Rockefeller Capital Management L.P. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYGet Rating) by 34.2% in the 3rd quarter, Holdings Channel reports. The firm owned 11,681 shares of the biopharmaceutical company’s stock after selling 6,067 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Alnylam Pharmaceuticals were worth $2,337,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Allworth Financial LP grew its position in shares of Alnylam Pharmaceuticals by 708.7% during the 3rd quarter. Allworth Financial LP now owns 186 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 163 shares during the period. SeaCrest Wealth Management LLC bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $44,000. Alta Advisers Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $80,000. Trust Co. of Vermont bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $100,000. Finally, SCHRODERS IS Ltd bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth about $74,000.

Analyst Ratings Changes

ALNY has been the subject of a number of recent analyst reports. The Goldman Sachs Group upped their price objective on shares of Alnylam Pharmaceuticals from $239.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, October 28th. Barclays reduced their price objective on shares of Alnylam Pharmaceuticals from $240.00 to $236.00 and set an “overweight” rating for the company in a research report on Friday, October 28th. StockNews.com initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Morgan Stanley reduced their price objective on shares of Alnylam Pharmaceuticals from $220.00 to $210.00 and set an “equal weight” rating for the company in a research report on Friday, October 28th. Finally, HC Wainwright dropped their target price on shares of Alnylam Pharmaceuticals from $430.00 to $415.00 and set a “buy” rating on the stock in a research note on Wednesday, November 2nd. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $239.84.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $228.11 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $117.58 and a 1 year high of $242.97. The company has a debt-to-equity ratio of 3.85, a current ratio of 3.48 and a quick ratio of 3.33. The stock has a market capitalization of $28.06 billion, a PE ratio of -23.35 and a beta of 0.50. The company’s 50 day simple moving average is $227.27 and its two-hundred day simple moving average is $207.35.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Rating) last issued its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported ($3.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.86) by ($1.46). The company had revenue of $264.31 million during the quarter, compared to the consensus estimate of $291.81 million. Alnylam Pharmaceuticals had a negative return on equity of 430.74% and a negative net margin of 123.02%. Alnylam Pharmaceuticals’s quarterly revenue was up 40.9% on a year-over-year basis. During the same period in the previous year, the company earned ($1.72) EPS. Analysts predict that Alnylam Pharmaceuticals, Inc. will post -9.64 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.

Recommended Stories

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYGet Rating).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.